RVMD vs. BNTX, TEVA, SMMT, GMAB, ASND, VTRS, RDY, QGEN, BBIO, and MRNA
Should you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), BridgeBio Pharma (BBIO), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.
Revolution Medicines vs. Its Competitors
Revolution Medicines (NASDAQ:RVMD) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.
94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 8.2% of Revolution Medicines shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Revolution Medicines has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.
In the previous week, Revolution Medicines had 31 more articles in the media than BioNTech. MarketBeat recorded 49 mentions for Revolution Medicines and 18 mentions for BioNTech. BioNTech's average media sentiment score of 0.71 beat Revolution Medicines' score of 0.41 indicating that BioNTech is being referred to more favorably in the news media.
Revolution Medicines currently has a consensus target price of $73.67, suggesting a potential upside of 60.09%. BioNTech has a consensus target price of $135.80, suggesting a potential upside of 36.88%. Given Revolution Medicines' stronger consensus rating and higher probable upside, equities analysts clearly believe Revolution Medicines is more favorable than BioNTech.
Revolution Medicines has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
Revolution Medicines has a net margin of 0.00% compared to BioNTech's net margin of -12.20%. BioNTech's return on equity of -1.84% beat Revolution Medicines' return on equity.
Summary
Revolution Medicines beats BioNTech on 9 of the 16 factors compared between the two stocks.
Get Revolution Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revolution Medicines Competitors List
Related Companies and Tools
This page (NASDAQ:RVMD) was last updated on 9/16/2025 by MarketBeat.com Staff
Free RVMD Stock Alerts